TPST
Tempest Therapeutics, Inc.
$1.26
+0.80%
$18.7M
No data for this timeframe.
Vol
Market Cap$18.7M
Cap SizeNano Cap
Inst. Holders10 funds
Inst. Value$638.0K
Insider Activity1B / 0S
Insider Net $$500.0K
SEC Reports7
Press Releases4
Recent Activity
Jun 4, 2026
other
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
<p align="justify">BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (
Jun 4, 2026
Insider
Richey William Drake was granted 25,000 shares
Director
May 29, 2026
SEC
Director Ms. Simantov resigned from the board of Tempest Therapeutics effective May 23, 2026, with no disagreement discl
8-K — Impact 2/10
May 29, 2026
Press
Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the
Impact 6/10
May 22, 2026
SEC
Tempest Therapeutics received a Nasdaq deficiency letter on May 19, 2026, for failing the minimum stockholders' equity r
8-K — Impact 8/10
May 22, 2026
SEC
Three board directors (Stephen Brady, Michael Raab, Christine Pellizzari) resigned from Tempest Therapeutics' board effe
8-K — Impact 5/10
Apr 29, 2026
Press
Tempest Therapeutics will present updated clinical data for TPST-2003 at the ISCT meeting, building on earlier positive
Impact 5/10
Mar 31, 2026
Insider
Trojanowski Justin was granted 22,000 shares
Corporate Controller
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.00 (Jan 2026)
Current $1.26
Low $11.00
Median $11.00
High $11.00
1 analysts
$11.00
$11.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 22, 2026 | HC Wainwright & Co. | UPGRADE | Neutral → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.30 | $-0.30 — $-0.30 | 86% YoY | 1 |
| Next Q | $-0.35 | $-0.35 — $-0.35 | 56% YoY | 1 |
| Current FY | $-1.34 ▲ +51.4% | $-1.34 — $-1.34 | 79% YoY | 1 |
| Next FY | $-1.21 ▲ +46.9% | $-1.21 — $-1.21 | 10% YoY | 1 |
Latest Reports
NEUTRAL
8-K
2/10
Director Ms. Simantov resigned from the board of Tempest Therapeutics effective May 23, 2026, with no disagreement discl
May 29, 2026
BEARISH
Press
6/10
Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proceeds by reducing the
May 29, 2026
BEARISH
8-K
8/10
Tempest Therapeutics received a Nasdaq deficiency letter on May 19, 2026, for failing the minimum stockholders' equity r
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $383.6K | — |
| VANGUARD FIDUCIARY TRUST CO | $113.0K | — |
| BlackRock, Inc. | $64.1K | — |
| FMR LLC | $54.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Richey William | A | $0.00 |
| Mar 31, 2026 | Trojanowski Justin | A | $0.00 |
| Mar 31, 2026 | Maestas Nicholas | A | $0.00 |
| Mar 24, 2026 | Angel Matthew | BUY | $500.0K |
| Feb 4, 2026 | Angel Matthew | A | $0.00 |
10 institutional holders with $638.0K total value (389,033 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 27 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 233,888 | $383.6K | 60.1% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 68,908 | $113.0K | 17.7% | — |
| 4 | BlackRock, Inc. | 39,068 | $64.1K | 10.0% | — |
| 5 | FMR LLC | 33,225 | $54.5K | 8.5% | — |
| 6 | DIMENSIONAL FUND ADVISORS LP | 11,444 | $18.8K | 2.9% | — |
| 7 | MORGAN STANLEY | 2,058 | $3.4K | 0.5% | — |
| 8 | JONES FINANCIAL COMPANIES LLLP | 239 | $413.00 | 0.1% | — |
| 9 | Vanguard Global Advisers, LLC | 168 | $276.00 | 0.0% | — |
| 10 | CITIGROUP INC | 8 | $13.00 | 0.0% | — |
4 unique insiders with 5 transactions. Net insider value: $500.0K ($500.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Richey William Drake | Director | AWARD | 25,000 | — | — |
| Mar 31, 2026 | Trojanowski Justin | Corporate Controller | AWARD | 22,000 | — | — |
| Mar 31, 2026 | Maestas Nicholas | Chief Financial Officer | AWARD | 140,000 | — | — |
| Mar 24, 2026 | Angel Matthew | CEO and President | BUY | 231,482 | $2.16 | $500.0K |
| Feb 4, 2026 | Angel Matthew | CEO and President | AWARD | 269,621 | — | — |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 3 neutral. Avg impact: 5.4/10.
NEUTRAL
8-K
2/10
Director Ms. Simantov resigned from the board of Tempest Therapeutics effective May 23, 2026, with n
May 29, 2026
BEARISH
8-K
8/10
Tempest Therapeutics received a Nasdaq deficiency letter on May 19, 2026, for failing the minimum st
May 22, 2026
BEARISH
8-K
5/10
Three board directors (Stephen Brady, Michael Raab, Christine Pellizzari) resigned from Tempest Ther
May 22, 2026
BEARISH
8-K
7/10
Tempest Therapeutics reported Q1 2026 results with a net loss of $27.7M ($2.53/share), significantly
May 14, 2026
NEUTRAL
EFFECT
4/10
Tempest Therapeutics' S-3 shelf registration (File No. 333-294740) became effective on April 3, 2026
Apr 6, 2026
NEUTRAL
S-3
4/10
Tempest Therapeutics filed an S-3 shelf registration to register 2,777,781 shares for resale by sell
Apr 2, 2026
BULLISH
8-K
8/10
Tempest Therapeutics announced positive interim clinical data from its REDEEM-1 trial for TPST-2003,
Feb 25, 2026
BEARISH
6/10
Tempest Therapeutics announced a warrant exercise agreement to immediately raise ~$2M in gross proce
May 29, 2026
BULLISH
5/10
Tempest Therapeutics will present updated clinical data for TPST-2003 at the ISCT meeting, building
Apr 29, 2026
MIXED
6/10
Tempest Therapeutics reported financial results for 2025, highlighted by a significant reduction in
Mar 30, 2026
BULLISH
7/10
Tempest Therapeutics selected Cincinnati Children’s AGCTC as its contract development and manufactur
Mar 11, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.00 mean target (Jan 2026)
$11.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $1.26 |
| Target Low | $11.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $11.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.30 | $-0.30 | $-0.30 | 85.5% | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.35 | $-0.35 | $-0.35 | 55.7% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.34 | $-1.34 | $-1.34 | 78.8% | +51.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.21 | $-1.21 | $-1.21 | 9.7% | +46.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.300 | |
| 7d ago | $0.000 | -0.300 |
| 30d ago | $0.000 | -0.300 |
| 60d ago | $0.000 | -0.300 |
| 90d ago | $0.000 | -0.300 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 22, 2026 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
<p align="justify">BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”
May 29, 2026
m_and_a
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
<p align="justify">BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage bi
May 14, 2026
earnings
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory mul
May 11, 2026
earnings_calendar
TPST Q1 2026 Earnings After Market Close — 2026-05-11
Apr 29, 2026
fda
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
<p align="justify">BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most
Apr 10, 2026
short_volume
Short Volume: TPST — 59.0% short (0.6M / 1.0M)
Short: 592,113 | Exempt: 11,297 | TRF Vol: 1,004,152 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
Tempest Reports Year End 2025 Financial Results and Provides Business Update
<p align="center">Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc.</p>
Mar 25, 2026
earnings_calendar
TPST Q4 2025 Earnings After Market Close — 2026-03-25
Mar 11, 2026
contract
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
<p align="justify">BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biot